Abstract
OBJECTIVE--To determine whether the finding of antiphospholipid antibodies in patients with venous thromboembolic episodes should influence the duration of treatment with anticoagulant drugs by mouth. METHODS--A retrospective study was carried out in 19 patients with antiphospholipid antibodies and a history of venous thromboembolic episodes. The median follow up from the first venous thromboembolic episode was 93 months and the median age at this episode was 26 years. The patients had in total 34 venous thromboembolic episodes. The total follow up period comprised 32 periods with and 23 periods without anticoagulant drugs. RESULTS--The probability of being free of recurrent venous thromboembolic episodes, calculated by the Kaplan-Meier method, was significantly influenced by the use of anticoagulant drugs. Patients receiving oral anticoagulants had at eight years a 100% probability of survival without recurrence, whereas patients in whom anticoagulant drugs were stopped had a 50% probability of a recurrent venous thromboembolic episode at two years, and a 78% probability of recurrence at eight years. CONCLUSION--Patients with venous thromboembolic episodes and antiphospholipid antibodies have a high risk for recurrent venous thromboembolic episodes and long term treatment with anticoagulant drugs by mouth is an effective prophylaxis.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Asherson R. A. A "primary" antiphospholipid syndrome? J Rheumatol. 1988 Dec;15(12):1742–1746. [PubMed] [Google Scholar]
- Asherson R. A., Baguley E., Pal C., Hughes G. R. Antiphospholipid syndrome: five year follow up. Ann Rheum Dis. 1991 Nov;50(11):805–810. doi: 10.1136/ard.50.11.805. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brey R. L., Hart R. G., Sherman D. G., Tegeler C. H. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology. 1990 Aug;40(8):1190–1196. doi: 10.1212/wnl.40.8.1190. [DOI] [PubMed] [Google Scholar]
- Finazzi G., Barbui T. A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis. ad hoc Study Group. Ric Clin Lab. 1990 Oct-Dec;20(4):245–252. doi: 10.1007/BF02900709. [DOI] [PubMed] [Google Scholar]
- Harris E. N. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol. 1990 Oct;94(4):476–484. doi: 10.1093/ajcp/94.4.476. [DOI] [PubMed] [Google Scholar]
- Harris E. N. Syndrome of the black swan. Br J Rheumatol. 1987 Oct;26(5):324–326. doi: 10.1093/rheumatology/26.5.324. [DOI] [PubMed] [Google Scholar]
- Hull R., Delmore T., Carter C., Hirsh J., Genton E., Gent M., Turpie G., McLaughlin D. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. 1982 Jan 28;306(4):189–194. doi: 10.1056/NEJM198201283060401. [DOI] [PubMed] [Google Scholar]
- Rosove M. H., Brewer P. M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992 Aug 15;117(4):303–308. doi: 10.7326/0003-4819-117-4-303. [DOI] [PubMed] [Google Scholar]
- Sammaritano L. R., Gharavi A. E., Lockshin M. D. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Semin Arthritis Rheum. 1990 Oct;20(2):81–96. doi: 10.1016/0049-0172(90)90021-7. [DOI] [PubMed] [Google Scholar]
- Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]